ASSAD MUKHTAR: Open Payments
NPI 1609259001 · MUNCIE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$554 in 25 payments from 11 companies in 2025. Trend: 2023 $16 · 2024 $493 · 2025 $554
Food & beverage: $554
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $270 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $41 |
| Neurocrine BioSciences, Inc. | 2 | $39 |
| Alkermes, Inc. | 2 | $36 |
| Luye Pharma (USA) Ltd. | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
Products named: VRAYLAR, CREON, ABILIFY MAINTENA, REXULTI, INGREZZA, ARISTADA, ERZOFRI EXTENDED-RELEASE, COBENFY.
Industry payments across IN — which companies pay providers there.
